1. Targeting the FXR Nuclear Receptor to Treat Liver Disease
Brent A. Neuschwander-Tetri 
Gastroenterology 
Volume 148, Issue 4, Pages (April 2015)
DOI: /j.gastro
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Obeticholic acid (OCA), a synthetic variant of the natural bile acid chenodeoxycholic acid, is a potent activator of the nuclear receptor farnesoid X receptor (FXR). Bile acids are the natural ligands for FXR and FXR activation decreases hepatocyte bile acid levels by decreasing hepatocyte uptake and synthesis of bile acids while increasing their biliary secretion, thus tightly regulating the bile acid pool. By decreasing the endogenous bile acid pool in patients on ursodeoxycholic acid (UDCA) for primary biliary cirrhosis, OCA decreased the potentially toxic endogenous bile acid pool which may reduce injury of the of biliary epithelium. FXR activation may also decrease lipogenesis and through this mechanism may have beneficial effects for nonalcoholic steatohepatitis (NASH). In both primary biliary cirrhosis (PBC) and NASH, decreasing the synthesis of bile acids from cholesterol also changed the serum cholesterol pool, but it is not clear if these changes are associated with an increased risk of cardiovascular disease.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions